Navigation Links
Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
Date:6/25/2010

CAMBRIDGE, Mass., June 25 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression. Anti-GITR agents have been identified by the National Cancer Institute as having high potential for treating cancer.  The preclinical data were presented and recognized as a distinguished abstract at the annual meeting of the Federation of Clinical Immunology Societies in Boston, Massachusetts.

The data included in the presentation demonstrated that a murine analog of TRX518, which is an anti-GITR antibody, resulted in pronounced and durable immune responses to several antigens in mice. These data also showed that the TRX518 analog, when combined with gemcitabine, a standard chemotherapeutic, significantly reduced tumor burden (p<0.001) and prolonged survival (p<0.001) in the mouse model when compared with gemcitabine alone. In particular, of the mice treated with the combination therapy, 65% had a complete remission. Similar findings were observed when the TRX518 analog was combined with cyclophosphamide. The humanized monoclonal antibody, TRX518, blocked the interaction of GITR with its ligand, enhanced the cytotoxicity of human natural killer cells, downmodulated GITR on peripheral blood lympocytes, did not induce appreciable cytokine release, and was well tolerated and safe at high doses in non-human primates.

"We are highly
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
2. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
10. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: ... first quarter financial results on Tuesday, April 21, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
(Date:4/16/2015)... 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) announced ... with a newly formed specialty healthcare company focused ... addressing urological disorders. The merged company, which is ... commenced operations and incorporates the pipeline assets of ... strategy is to build a late-stage and commercial ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... April 18, 2015 Carinsurancehints.com has released a ... plans that offer financial protection against fire damage. ... pay benefits in case their vehicle is set intentionally on ... caused by rioting or by other things. , It ... on a single website http://www.carinsurancehints.com/ , in just ...
(Date:4/18/2015)... PITTSBURGH, PA (PRWEB) April 18, 2015 ... so I decided to create a healthful juice ... an inventor from Rosedale, Md. "It increases my ... overall healthy body." , He developed Tapp's Juice ... The juice helps to prevent physical and mental ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post explaining ... , Clients can review important auto insurance quotes ... provides important advantages for clients who need affordable financial ... not have coverage for their vehicles can purchase a ... hour. Many agencies offer important discounts and drivers can ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... BATESVILLE, Ind., Feb. 8 Hillenbrand,Industries, Inc. (NYSE: ... of $0.285 per share. This dividend was declared by ... payable on March 31, 2008 to,shareholders of record at ... ABOUT HILLENBRAND INDUSTRIES, INC., Hillenbrand Industries is organized ...
... sees greater activation of key brain region than found in ... a video game "widow," science might now be able to ... shows that the part of the brain associated with reward ... when both genders played a game whose object was to ...
... 3 Program of CGT-2168, MENLO PARK, ... named a distinguished international panel of medical ... charged with overseeing COGENT,the company,s global Phase ... antiplatelet product CGT-2168., (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ...
... happy and healthy ... control, WESTPORT, Conn., Feb. 8 Just in ... diabetes information,inspiration, and connection, has a spicy and informative ... people with diabetes.,Accessible at http://www.dlife.com/diabetes-valentines, the quiz ...
... sales of $20.4 million versus $24.1 ... million in the same quarter last year., - ... initial shipments expected during the second half of fiscal 2008., ... ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer and marketer ...
... Stereotaxis, Inc. (Nasdaq:,STXS), announced today that Bevil ... Chief Financial Officer, will present at the Deutsche ... Carlton Hotel in Naples,Florida on Thursday, February 14, ... at the conference is by invitation only. The ...
Cached Medicine News:Health News:For Males, Video Game Rewards Are All in the Mind 2Health News:For Males, Video Game Rewards Are All in the Mind 3Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 2Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 3Health News:Love and Diabetes: dLife Valentine's Day Quiz Tests and Teaches Important Relationship Lessons for People With Diabetes 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 3Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 4Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 5
Soft silicone brush tip allows atraumatic brushing and manipulation of retina surface. Silicone brush extends 3mm beyond end of cannula. Luer lock hub for easy, secure connection to a backflush handl...
Maumenee vitreous aspirating cannula, 18 gauge....
Reusable cannula with .90 mm (20 g) shaft, tapering to .60 mm (23 g) 3 mm from the tip. Overall length is 29 mm....
... silicone tip cannula allows atraumatic ... hole for aspiration of subretinal ... 6mm beyond end of cannula. ... easy, secure connection to a ...
Medicine Products: